Shawn X. Sun

Director, Global Evidence and Outcomes
Takeda Development Center Americas, Inc.

Shawn X. Sun is a Director of Global Evidence & Outcomes at Takeda Pharmaceuticals. Prior to Takeda, he had worked in the HEOR area at several other pharmaceutical companies. He leads the strategy development and evidence generation in clinical, economic, and patient-centered outcomes for various pipeline and marketed products. Before joining the pharmaceutical industry, he was a HEOR manager at Walgreens, responsible for evaluating effectiveness of clinical programs and conducting HEOR studies for pharmaceutical companies.
Dr. Sun received his PhD from Duke University and did his postdoctoral fellowship in Pharmacoeconomics from University of North Carolina at Chapel Hill.

Presentation(s):

PB0685 - A Retrospective Database Analysis Study to Evaluate Disease Burden and Treatment Patterns Among Patients With Hemophilia A in China
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0824 - Characteristics and Clinical Burden Among Patients With von Willebrand Disease Eligible for Prophylaxis: Results From a Retrospective US Cohort Study
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0825 - Burden of Illness in Patients With von Willebrand Disease Receiving Prophylaxis Versus Potential Prophylaxis-Eligible Patients: A Post-Hoc Analysis of A European Socioeconomic Study
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0826 - A Systematic Review of Acquired von Willebrand Syndrome Associated With Cardiac Disorders: Epidemiology, Disease Burden, and Management
Monday, July 11, 2022
6:30 PM – 7:30 PM
PB0827 - A Systematic Review of Acquired von Willebrand Syndrome Associated With Non-Cardiac Diseases: Epidemiology, Disease Burden, and Management
Monday, July 11, 2022
6:30 PM – 7:30 PM